In regulated trials, stem cell therapy looks fairly safe. Across 55 trials and 2,696 patients, cells given into a vein or artery made fever more common. Infections, blood clots, deaths and cancers did not rise (Meta-analysis). The bigger danger comes from products sold by unregulated clinics: contaminated cord-blood vials once infected 20 people in 8 states (Study).
The anti-aging case is thinner than the ads suggest. The best evidence so far shows a modest walking gain in frail older adults (Trial). It does not show slower aging.
Stem Cells vs Exosomes
Clinics sell two kinds of product. The first is mesenchymal stem cells, or MSCs. These are support cells grown from bone marrow, fat or umbilical cord tissue. The FDA calls them mesenchymal stromal cells, after the support tissue that holds organs together (Source).
Your own cells, often taken from your fat, are called autologous. Cells from a donor are allogeneic. An FDA alert names the most widely promoted products: those made from fat, cord blood, Wharton’s jelly and amniotic fluid (Source). Wharton’s jelly is the soft tissue inside the umbilical cord.
The second product is exosomes, tiny sacs that cells release into the fluid around them. Scientists call them extracellular vesicles (Review). They are not cells, so they cannot grow or divide.
In March 2021, a count found 1,480 US businesses selling unlicensed stem cell products at 2,754 clinics. That was more than four times as many businesses as five years earlier (Study). Pain was the top claim, at 85% or more, and others ran “all the way to hair loss and anti-aging” (Source).
In 2019, the FDA warned that some clinics were now also offering exosomes. Among them were “some that manufacture or market illegal ‘stem cell’ products” (Source). A 2025 review that looked only at skin uses found just 12 clinical studies. They covered aging skin, acne scars, hair loss and wounds. The authors noted that large trials, where a coin flip decides who gets the treatment, are still missing (Review).
What the Frailty Trials Found
The best case for stem cells against aging comes from frailty. That is the loss of strength, energy and walking speed that some people develop in old age. Two trials tested donor MSCs in frail older adults, and they share a senior author, Joshua Hare. Both used the 6-minute walk test, which measures how far you can walk in six minutes.
The first, published in 2017, had just 30 people with an average age of about 75. A coin flip decided who got 100 million cells, 200 million cells or a dummy infusion, with 10 people in each group (Trial).
After six months, the group on 100 million cells walked about 65 meters further than at the start. The other two groups showed no clear change. Yet the groups did not clearly differ from each other, apart from one marker of inflammation (Trial). The authors said a proper test would need about 30 people per group. No one had a serious side effect blamed on the cells (Trial).
The bigger follow-up came out in 2026. It gave 148 frail adults aged 70 to 85 one infusion of a donor-cell product called laromestrocel. Each person got one of four doses, or a placebo (Trial). Before treatment, most could walk about 300 meters in six minutes.
At nine months, people on the top dose walked about 63 meters further than the placebo group. At six months the gap was about 41 meters, small enough that chance could explain it (Trial). People also rated their own physical function. On that measure, the cell groups showed no clear difference from placebo (Trial).
Both walk numbers come from the top-dose group, which had just 16 people. One lower dose also showed a clear gain at nine months, of about 49 meters. The paper reports no clear gain for the other two doses. The team’s main planned test compared the doses with placebo at six months, and it fell short. A second planned check did pass: it looked for gains that grow as the dose goes up (Trial).
On safety, the trial looked reassuring. Serious side effects were about as common in every group. Two people died, one on a middle dose and one on placebo, and neither death was blamed on the cells (Trial).
Longeveron, the company that makes the cells, sponsored the trial. The trial’s registry page showed no posted results when we checked (Source). Eleven of the 25 authors list ties to the company. Hare is the company’s chief scientific officer and owns shares in it (Trial).
Walking further is a real gain for a frail person, but it does not prove a longer life or reversed aging. The 2026 trial reported no measure of biological age, aging clock or lifespan (Trial). A 2023 review of 20 stem cell trials for aging found they mostly measured frailty, walking distance, inflammation, safety and skin. No stem cell product for frailty had reached the final, large stage of testing (Review). We cover two other longevity ideas, cellular reprogramming and plasma exchange, in their own posts.
How Safe Is Stem Cell Therapy?
The best safety data come from trials, where every side effect gets counted and compared. One big review combined 55 trials with 2,696 patients, mostly adults. In each one, a coin flip decided who got MSCs into a vein or artery (Meta-analysis).
Fever was the one harm that rose. Infections, blood clots, cancer and other reactions to the drip were no more common in people who got cells (Meta-analysis). Deaths were somewhat lower in the cell groups. The authors reported that as a safety finding, not as proof that the cells save lives. The review did not combine results on whether the treatments worked (Meta-analysis).
None of the 55 trials was stopped early for safety reasons. People were followed for one day to five years, about 14 months on average (Meta-analysis).
Other reviews agree. A 2012 review of 36 studies linked MSCs only to a passing fever (Meta-analysis). A 2021 review of 62 trials and 3,546 people also counted cells injected into tissue. It found more short-lived fever, plus weaker, less certain links to injection-site reactions, constipation, tiredness and poor sleep. Deaths and infections were no more common than in the comparison groups. Only the fever link held up in the best-quality trials (Meta-analysis).
This record has clear limits. The big review covers only cells given into a vein or artery, mostly for heart, brain, immune and liver disease. Each side effect was counted in only some of its trials (Meta-analysis). Only 6 of the 55 passed every check for the flaws that can make a treatment look better than it is. Only 7 fully confirmed what their cells were (Meta-analysis).
So this record says nothing about a clinic’s cord-blood vial, a joint injection of untested product, or exosomes. A 2023 review adds that cells dripped into a vein may get trapped in the lungs, which could raise safety concerns (Review). Rare harms, and harms that take years to show, need bigger and longer studies to rule out.
What Goes Wrong at Clinics
In 2018, the CDC traced a cluster of infections to clinic products made from umbilical cord blood (Source). The final count was 20 people in 8 states (Study).
Most had sought help for pain, osteoarthritis or an injury. Sixteen had the product injected into a joint. Nineteen of the 20 ended up in hospital. The typical stay was 9 days, and stays ran as long as 58. Most of the bacteria were gut bugs such as E. coli (Study).
The contamination was already in the vials. Of 34 unopened vials that had never been shipped out, 22 grew bacteria. Gene tests pointed to one shared source of the bacteria, most likely during processing. The product was not FDA-approved and was not given under an FDA trial permit (Study).
In 2017, doctors described three women with age-related macular degeneration, an eye disease that blurs central vision in later life. Each paid $5,000 at a US clinic. There, cells from her own fat were injected into both eyes on the same day (Study).
Before the injections, their vision ranged from 20/30, near normal, to 20/200. A year later it ranged from 20/200 to no light perception at all, which means total blindness. The authors report that the retina came loose in all six eyes (Study). This report covered just three people and was not a trial. Still, the harm was severe.
The FDA has warned about exosomes too. In December 2019, it reported “multiple recent reports of serious adverse events” among patients in Nebraska. They had been given unapproved products marketed as containing exosomes (Source). The agency did not say how many people were hurt or how.
What Is Approved and Legal
The FDA’s consumer page was last updated in April 2024. It says the only approved stem cell products are blood-forming cells from umbilical cord blood. They treat disorders that affect how the body makes blood, and they are not approved for other uses. The page also says “there are currently no FDA-approved exosome products” (Source). One approval has come since.
On December 18, 2024, the FDA approved Ryoncil, made from the bone marrow of healthy adult donors. It is the first approved MSC therapy (Source). The approval covers one use: graft-versus-host disease in children 2 months and older, when steroids have not worked. In this disease, which can follow a transplant, donor immune cells attack the patient’s body. The approval rested on one study of 54 children, with no comparison group.
The FDA also keeps a list of approved cell and gene therapies. Its September 2026 update lists 9 cord-blood stem cell products and Ryoncil, but no exosome product (Source).
A Florida law that took effect on July 1, 2025, lets doctors use stem cell therapy the FDA has not approved. The therapy must fit the kind of care the doctor is licensed to give. It must also relate to “orthopedics, wound care, or pain management” (Source). The words “aging,” “longevity” and “exosome” never appear in the text.
The law’s definition of covered cell products leaves out “secreted or extracted human products,” such as “cell factors” (Source). Cells secrete exosomes, so by our reading the law does not cover them. Doctors who use the law must say in every ad that the therapy is not FDA-approved. Patients must also sign a consent form that lists its risks (Source).
A state law cannot switch off federal rules. A Florida House staff analysis cites the state health department. It warns that the law may leave doctors and suppliers open to FDA action (Source). That can mean warning letters, court orders, criminal cases and product recalls (Source). Lawyers at one national firm call the law “in direct conflict with federal law” (Source).
Questions to Ask a Clinic
Four questions can help you tell a real trial from a sales pitch.
Is there an IND number? An investigational new drug application, or IND, is how a sponsor gets FDA clearance to test an unapproved product in people. The FDA tells patients to ask for the IND number and for proof that the FDA acknowledged it (Source).
Is it registered, and who reviewed it? A listing on ClinicalTrials.gov, the US trial registry, is not proof on its own. In the eye case, one woman found the clinic through its listing there and believed she was in a trial (Study).
Yet none of the three consent forms mentioned a trial. The listed study was withdrawn before it enrolled anyone. The authors note that clinics like this often list studies that patients pay for. These have an ethics board’s approval but no IND (Study). A 2017 study found many US stem cell businesses recruiting through “pay-to-participate” studies on the registry (Study). So ask whether the FDA reviewed the study, not just an ethics board.
Am I paying to take part? In an FDA trial, a sponsor may charge for the product only as an exception. It needs written FDA permission first and must meet strict conditions. Even then, it may charge only direct costs, with no profit (Source). Two bioethicists flagged a pay-to-participate study in Panama that charged $7,200 per child plus travel. By their account, the published paper never mentioned the charge (Source).
Where are the cells made, and how are they tested? The cord-blood outbreak most likely came from contamination during processing (Study). Ask who made the product and whether each batch is tested for bacteria. Then ask to see the results.
Frequently Asked Questions
Is Stem Cell Therapy FDA Approved?
A few products are, for narrow uses. Blood-forming stem cells from cord blood are approved for disorders that affect blood production, and not for other uses (Source). Ryoncil is approved only for children with graft-versus-host disease that steroids did not help (Source). No stem cell product is approved for anti-aging.
Is Stem Cell Therapy Legal in the US?
It is clearly legal for the approved uses and inside an FDA-regulated trial. According to one law firm, FDA rules bar marketing cell products for pain, wounds or joint problems without FDA approval (Source). Florida now allows some unapproved therapies for orthopedics, wound care and pain (Source). The same lawyers say that clashes with federal law.
Does Stem Cell Therapy Work?
For some blood disorders, cord-blood stem cells are an approved treatment (Source). For aging, the evidence is early. In a trial of 148 frail adults, the top dose added about 63 meters of walking at nine months. At six months, the gain was not clear (Trial).
Stem Cell Therapy vs Exosomes?
Stem cell therapy uses living cells, while exosomes are tiny sacs that cells release. For skin uses alone, a 2025 review found just 12 clinical studies and said large trials are still missing (Review). No exosome product is FDA-approved, and the FDA has warned of serious side effects from unapproved ones (Source).
Key Takeaways
- Trial-grade cells look fairly safe. In 55 trials, cells given into the bloodstream raised fever, but not infection, clots, death or cancer (Meta-analysis).
- The anti-aging signal is modest. In a company-sponsored trial of 148 frail adults, the top dose added about 63 meters of walking at nine months. The gain at six months was not clear (Trial).
- Clinic product can be contaminated. Cord-blood vials infected 20 people in 8 states, and 22 of 34 unopened vials grew bacteria (Study).
- No exosome product is approved. The FDA has warned of serious side effects from unapproved exosome products (Source).
- Ryoncil’s approval is narrow. It covers one use: graft-versus-host disease in children when steroids have failed (Source).
- Ask for the IND, and ask who pays. An FDA trial may charge only as an exception, and only with written FDA permission (Source).
Choose a Regulated Trial
Stem cell science is real, and parts of it look promising, but it is early. The frailty gains are small, and the cell maker sponsored the bigger trial. Nobody has shown that cells slow aging itself.
If you want to try it, the safer way in is a regulated trial. Search ClinicalTrials.gov, then check the IND number, the sponsor and who pays. A cash-pay infusion at a wellness clinic may not be the same product, even when the brochure quotes the same research.
Take the paperwork to your own doctor before you sign anything. If a clinic will not answer these questions, treat that as a warning sign.
The research is worth following. Until it matures, a few good questions are your best protection.
This article is for educational purposes and is not medical advice. Talk to a qualified clinician before changing your health regimen.
Leave a Reply